TIDMGENI
RNS Number : 3343Z
GENinCode PLC
15 May 2023
GENinCode Plc
("GENinCode" or the "Company")
Collaboration with University Clinic Dresden for implementation
of LIPID inCode (R)
LIPID inCode(R) becomes first polygenic test for CVD implemented
in Germany
Oxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics
company focused on the prevention of cardiovascular disease,
announces its collaboration with the University Clinic Dresden,
Department of Internal Medicine and Department of Human Genetics,
based in Germany, to use its LIPID inCode(R) test in primary care
for the diagnosis of hypercholesterolemia (high levels of
cholesterol) and familial hypercholesterolemia ("FH"). LIPID
inCode(R) is the first polygenic product to be introduced in
Germany to improve the diagnosis and treatment of
hypercholesterolemia to prevent cardiovascular disease ("CVD").
This new endeavour is based on a long-standing clinical research
collaboration of GENinCode with the Department of Medicine (Prof.
Dr. S. Bornstein).
The University Clinic lipid centre treats over 6000 patients
with lipid disorders and constitutes the largest academic lipid
apheresis centre globally. In Germany, 60% of the population suffer
from high levels of cholesterol and it is estimated that over a
quarter of a million of these cases relate to FH(1) . The
collaboration also builds on the Transcampus Initiative between
Technische Universität in Dresden and Kings College London,
providing a translational model of best practice and patient care
across borders.
LIPID inCode(R) testing will initially support the lipid centre
in the region of Saxony to deliver its preventative care plans to
identify individuals at risk of CVD. The lipid centre, will handle
the regional roll-out of testing and may extend testing to other
regions of Germany. LIPID inCode(R) improves the diagnosis and
treatment of familial hypercholesterolemia with rapid turnaround of
test results to prevent the onset of CVD. It is also the first
commercially available polygenic test for CVD to be implemented in
Germany.
The collaboration follows the positive results of the LIPID
inCode(R) Dresden clinical study and pilot. LIPID inCode(R) testing
in the Saxony region will cover a primary care population and
community practice in the region. Testing will diagnose patients
with genetic disorders giving rise to high levels of cholesterol,
an important risk factor for the development of CVD. Improved
detection supports better treatment and preventative care.
In the Germany around 6 million people live with cardiovascular
disease, which causes 25% of all deaths annually, with the disease
rate particularly high in the region of Saxony(2) . CVD can be
reduced by identifying and treating individuals at risk and the
collaboration will focus on addressing CVD prevention, including
identifying individuals with hypercholesterolemia and particularly
those with FH.
FH is an inherited monogenic condition which affects an
individual's ability to regulate and remove cholesterol from their
blood. For individuals suffering with FH, it is important to lower
cholesterol to healthy levels as early in life as possible, often
requiring medicines such as statins or more aggressive treatment to
help better control cholesterol levels.
GENinCode has a vision to assist clinicians and inform patients
in interpreting cardiovascular risk, and to improve public health
using the predictive capability of genomics. High genetic risk
patients are assisted in making lifestyle choices and can receive
targeted treatment to improve outcomes. Over the past 15 years
GENinCode has made a substantial investment in its research,
bioinformatic data, technology, and product development to assess
disease risk, in order to help clinicians and patients prevent the
onset of CVD.
Matthew Walls, CEO of GENinCode PLC, said: "The collaboration
with the University Clinic in Dresden will focus on the use of
Lipid inCode(R) testing to identify patients at high risk of heart
disease, the largest cause of death in the Germany. The Dresden hub
will handle regional testing and extend testing to other regions of
Germany for the adoption of our globally leading polygenic test. We
look forward to supporting the Dresden Lipid Centre in reaching its
plans to provide early diagnosis of patients with
hypercholesterolemia and prevent CVD."
Professor Stefan Bornstein, Chair and Director of Medicine of
the University Hospital and Transcampus Dean Kings College London,
commented : "We are delighted to collaborate with GENinCode to
implement Lipid inCode(R) for the diagnosis and treatment of
hypercholesterolemia and familial hypercholesterolemia. This
collaboration marks a major step to improve our primary care
practice for the identification of FH sufferers and we welcome this
approach to work together with our UK colleagues as part of the
German and UK Transcampus programme to reduce the onset of
cardiovascular disease."
For more information visit www.genincode.com
Enquiries:
GENinCode Plc www.genincode.com or via Walbrook PR
Matthew Walls, CEO
Stifel Nicolaus Europe Limited (Nomad and Joint Broker) Tel: +44 (0)20 7710 7600
Alex Price / Ben Maddison / Richard Short
Cenkos Securities Plc (Joint Broker) Tel: +44 (0)20 7397 8900
Giles Balleny
Dale Bellis / Michael Johnson (Sales)
Walbrook PR Limited Tel: 020 7933 8780 or genincode@walbrookpr.com
Anna Dunphy / Louis Ashe-Jepson / Phillip Marriage
About GENinCode:
GENinCode Plc is a UK based company specialising in genetic risk
assessment of cardiovascular disease. Cardiovascular disease is the
leading cause of death and disability worldwide.
GENinCode operates business units in the UK, Europe through
GENinCode S.L.U, and in the United States through GENinCode U.S.
Inc.
GENinCode predictive technology provides patients and physicians
with globally leading preventative care and treatment strategies.
GENinCode CE marked invitro-diagnostic molecular tests combine
clinical algorithms and bioinformatics to provide advanced patient
risk assessment to predict disease onset.
About University Clinic Dresden, Department of Medicine and
Department of Human Genetics :
The University Clinic Dresden, Department of Internal Medicine
III, under the direction of Clinic Director Prof. Dr. Stefan R.
Bornstein - with more than 250 employees in medical, nursing,
technical and administrative services as well as in research - is
one of the leading centres in Germany and Europe in the field of
treatment and research of diabetes mellitus type 1 and 2 as well as
its secondary diseases and lipid disorders. The clinic is home to
the only active islet cell transplantation programme in Germany at
present, the interdisciplinary vascular centre and the special
outpatient clinics for rheumatology, metabolism, diabetic foot,
insulin pumps, angiology, nephrology, endocrinology as well as the
emergency room and the intensive care unit of internal medicine.
The department of human genetics has extensive expertise in the
analysis of common and rare genetic diseases and is also an
integral part of the cancer centre .
About cardiovascular disease (CVD)
CVD is a broad disease classification which encompasses
conditions such as coronary artery disease (causing angina, heart
attacks, heart failure), cerebrovascular disease (causing stroke,
and some dementia), peripheral vascular disease (causing limb
ischemia, and some chronic kidney disease) and venous
thromboembolism. CVD is the leading cause of death and disability
worldwide accounting for one in every four deaths in the United
States. According to the US National Institutes of Health (NIH), by
2030, the global cost of CVD is set to rise to US$1,044 billion,
from approximately US$863 billion in 2010, and is both a major
health issue and global economic burden(3) .
(1) Prevalence of dyslipidemia among adults in Germany: results
of the German Health Interview and Examination Survey for Adults
(DEGS 1)] - PubMed (nih.gov)
(2) Regional Differences in the Prevalence of Cardiovascular
Disease - PMC (nih.gov)
(3) Data-driven quality improvement program to prevent
hospitalisation and improve care of people living with coronary
heart disease: Protocol for a process evaluation - PMC
(nih.gov)
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCGPUQCAUPWGCW
(END) Dow Jones Newswires
May 15, 2023 02:00 ET (06:00 GMT)
Genincode (LSE:GENI)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Genincode (LSE:GENI)
Gráfica de Acción Histórica
De May 2023 a May 2024